ストックスクリーナーアプリを入手
532.78
1.12%
-12.22
アフターアワーズ：
532.78
前日終値:
$545.00
開ける：
$545
24時間の取引高:
722.92K
Relative Volume:
1.27
時価総額：
$22.85B
収益：
$3.17B
当期純損益:
$1.29B
株価収益率:
19.66
EPS:
27.0947
ネットキャッシュフロー:
$1.01B
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
+8.22%
6か月 パフォーマンス:
-7.36%
1年 パフォーマンス:
+20.04%
1日の値動き範囲:
$524.79
$545.00
1週間の範囲:
$524.79
$577.02
52週間の値動き範囲:
$409.07
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
名前
United Therapeutics Corp
セクター
電話
(301) 608-9292
住所
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
532.78 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
18.50 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.20 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.255 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.06 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Raymond James | Outperform |
| 2025-10-20 | 開始されました | Wells Fargo | Underweight |
| 2025-09-26 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-06-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-07-11 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | アップグレード | Goldman | Sell → Neutral |
| 2024-02-05 | 開始されました | Leerink Partners | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2022-12-06 | 開始されました | UBS | Buy |
| 2022-12-05 | 開始されました | Goldman | Sell |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-20 | 繰り返されました | BofA Securities | Underperform |
| 2022-09-19 | 再開されました | Wedbush | Outperform |
| 2022-02-11 | 開始されました | BTIG Research | Neutral |
| 2021-07-14 | アップグレード | Argus | Hold → Buy |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-02-01 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-06-25 | 繰り返されました | H.C. Wainwright | Neutral |
| 2020-03-10 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-27 | アップグレード | Cowen | Market Perform → Outperform |
| 2020-01-31 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 開始されました | BofA/Merrill | Underperform |
| 2019-08-01 | アップグレード | Jefferies | Underperform → Hold |
| 2019-08-01 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | アップグレード | UBS | Sell → Neutral |
| 2019-05-09 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | アップグレード | Standpoint Research | Hold → Buy |
| 2018-08-08 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 繰り返されました | Barclays | Underweight |
| 2018-01-18 | 再開されました | Credit Suisse | Underperform |
| 2017-12-27 | 繰り返されました | Wedbush | Outperform |
| 2017-04-27 | 繰り返されました | Wedbush | Outperform |
| 2017-03-30 | 開始されました | UBS | Sell |
| 2017-03-16 | 開始されました | Credit Suisse | Underperform |
すべてを表示
United Therapeutics Corp (UTHR) 最新ニュース
United Therapeutics Corp Stock (UTHR) Moved Up by 7.26% on Oct 1: What Investors Need To Know - TradingKey
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback - Zacks Investment Research
This United Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% - TradingView
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet - FinancialContent
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More - Yahoo Finance
United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia - Benzinga
Cantor Fitzgerald reiterates United Therapeutics stock rating after patent win - Investing.com
BTIG upgrades United Therapeutics stock rating on legal win - Investing.com
Why is United Therapeutics stock gaining today? - Investing.com
United Therapeutics Corporation wins Yutrepia PH‑ILD patent ruling - Mugglehead Investment Magazine
Liquidia Corp. Shares Edge Higher After HoursUnited Therapeutics (NASDAQ:UTHR), Liquidia (NASDAQ:LQDA) - Benzinga
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today - Yahoo Finance
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia - Yahoo Finance
United Therapeutics (UTHR) Shares Surge 13% After Favorable Pate - GuruFocus
Liquidia Loses Bid to Nix United Therapeutics Lung-Drug Patent - Bloomberg Law News
A Look at United Therapeutics Corp (UTHR) After 12.6% Gain -- GF Value $428.32 vs Price $541.89 - GuruFocus
A CEO’s trust exercises options and sells 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
United Therapeutics jumps 13% on court ruling (UTHR:NASDAQ) - Seeking Alpha
U.S. Markets Finished Mixed Wednesday As United Therapeutics Led, Jabil Lagged - Barron's
LQDA Stock Eyes Worst Day Ever After Judge Upholds Two UTHR Patent Claims - Yahoo Finance
Liquidia slumps after US court rules for United Therapeutics in patent fight - Yahoo Finance
UTHR Stock Jumps As Tyvaso Win And Massive Buyback Fuel Momentum - StocksToTrade
Liquidia shares crater after court rules for United Therapeutics - uk.finance.yahoo.com
Liquidia plunges after court ruling in United Therapeutics patent fight (LQDA:NASDAQ) - Seeking Alpha
United Therapeutics Corp Stock (UTHR) Moved Up by 12.20% on Sep 30: Key Drivers Unveiled - TradingKey
After exercising options, a family trust sold 9,500 United Therapeutics (UTHR) shares under a trading plan. - Stock Titan
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts - Yahoo Finance
After exercising stock options, the CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics (UTHR) Falls On Goldman Sell Call, Is It Still 29% Undervalued? - Yahoo Finance
United Therapeutics Corporation (UTHR) stock price, news, quote and history - Yahoo Finance Australia
United Therapeutics chairperson & CEO sells $4.7m in stock By Investing.com - Investing.com South Africa
United Therapeutics chairperson & CEO sells $4.7m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 26 September By Investing.com - Investing.com UK
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
After exercising stock options, the CEO's family trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan
United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions - Yahoo Finance
UTHR News | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Why United Therapeutics (UTHR) Shares Are Falling Today - Yahoo Finance
United Therapeutics Corporation (UTHR) Stock Price, News, Quote & History - Yahoo! Finance Canada
A Look at United Therapeutics Corp (UTHR) After 3.5% Decline -- GF Value $427.97 vs Price $472.21 - GuruFocus
United Therapeutics CEO Rothblatt sells $4.67m in stock after option exercise - Investing.com Nigeria
Form 4 United Therapeutics Corporation For: 24 September - Investing.com India
Form 4 United Therapeutics Corporation For: 24 September By Investing.com - Investing.com Canada
United Therapeutics Insider Sold Shares Worth $4,669,918, According to a Recent SEC Filing - marketscreener.com
After exercising 9,500 options, family trusts sold United Therapeutics (UTHR) shares under a pre-arranged plan. - Stock Titan
United Therapeutics Falls as Goldman Sachs Sets $321 Price Target - citybiz
United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR) - Seeking Alpha
United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate - ChartMill
United Therapeutics Corp (UTHR) 財務データ
収益
当期純利益
現金流量
EPS
United Therapeutics Corp (UTHR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 06 '26 |
Sale |
538.67 |
9,500 |
5,117,412 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 05 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 05 '26 |
Sale |
541.64 |
9,500 |
5,145,537 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 02 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 02 '26 |
Sale |
549.37 |
9,500 |
5,219,015 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 01 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Oct 01 '26 |
Sale |
576.47 |
9,500 |
5,476,462 |
324,443 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Oct 01 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Oct 01 '26 |
Sale |
564.95 |
8,300 |
4,689,051 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 30 '26 |
Sale |
550.22 |
1,920 |
1,056,425 |
324,443 |
0.99%
2.42%
大文字化:
|
ボリューム (24 時間):